Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Total Debt (2017 - 2025)

Historic Total Debt for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $30.6 million.

  • Innate Pharma's Total Debt fell 1997.5% to $30.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $30.6 million, marking a year-over-year decrease of 1997.5%. This contributed to the annual value of $33.5 million for FY2024, which is 2226.01% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Total Debt is $30.6 million, which was down 1997.5% from $33.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Total Debt ranged from a high of $50.6 million in Q4 2021 and a low of $19.9 million during Q2 2021
  • In the last 5 years, Innate Pharma's Total Debt had a median value of $42.9 million in 2023 and averaged $38.8 million.
  • As far as peak fluctuations go, Innate Pharma's Total Debt plummeted by 9989.44% in 2021, and later soared by 13289.27% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Total Debt stood at $50.6 million in 2021, then dropped by 14.85% to $43.1 million in 2022, then dropped by 0.43% to $42.9 million in 2023, then dropped by 22.84% to $33.1 million in 2024, then fell by 7.62% to $30.6 million in 2025.
  • Its Total Debt stands at $30.6 million for Q2 2025, versus $33.1 million for Q4 2024 and $38.2 million for Q2 2024.